Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1976 2
1977 5
1978 5
1979 4
1980 6
1981 4
1982 2
1983 3
1984 3
1985 1
1986 1
1987 3
1988 4
1989 1
1990 3
1991 1
1992 1
1993 1
1994 3
1995 1
2001 1
2004 1
2005 2
2006 1
2007 3
2008 1
2009 2
2010 4
2011 4
2012 4
2013 7
2014 9
2015 8
2016 3
2017 15
2018 12
2019 15
2020 7
2021 19
2022 12
2023 12
2024 19
2025 19

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

218 results

Results by year

Filters applied: . Clear all
Page 1
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Klencke BJ, Ro S, Donahue R, Kawashima J, Mesa R; MOMENTUM Study Investigators. Verstovsek S, et al. Lancet. 2023 Jan 28;401(10373):269-280. doi: 10.1016/S0140-6736(22)02036-0. Lancet. 2023. PMID: 36709073 Clinical Trial.
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3.
Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly L, Kim HJ, Mikesch JH, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Geller NL, Hasabou N, Delgado D, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Wittsack H, Mendizabal A, Devine SM, Horowitz MM, Chen YB; BMT-CTN 1506/MORPHO Study Investigators. Levis MJ, et al. J Clin Oncol. 2024 May 20;42(15):1766-1775. doi: 10.1200/JCO.23.02474. Epub 2024 Mar 12. J Clin Oncol. 2024. PMID: 38471061 Free PMC article. Clinical Trial.
Immuno-Oncology for Gynecologic Malignancies.
How JA, Patel A, Jazaeri AA. How JA, et al. Adv Exp Med Biol. 2021;1342:193-232. doi: 10.1007/978-3-030-79308-1_6. Adv Exp Med Biol. 2021. PMID: 34972966 Review.
Immuno-oncology for Gynecologic Malignancies.
How J, Patel A, Jazaeri A. How J, et al. Adv Exp Med Biol. 2020;1244:149-182. doi: 10.1007/978-3-030-41008-7_7. Adv Exp Med Biol. 2020. PMID: 32301014 Review.
Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial.
How JA, Dang M, Lee S, Fellman B, Westin SN, Sood AK, Fleming ND, Shafer A, Yuan Y, Liu J, Zhao L, Celestino J, Hajek R, Morgan MB, Parra ER, Laberiano Fernandez CD, Arrechedera CA, Solis Soto LM, Schmeler KM, Nick A, Lu KH, Coleman R, Wang L, Jazaeri AA. How JA, et al. Med. 2025 Jan 10;6(1):100494. doi: 10.1016/j.medj.2024.07.022. Epub 2024 Aug 15. Med. 2025. PMID: 39151421 Clinical Trial.
Myeloproliferative Neoplasms and Cardiovascular Disease: A Review.
Leiva O, Liu O, Zhou S, How J, Lee M, Hobbs G. Leiva O, et al. Among authors: how j. Curr Treat Options Oncol. 2024 Oct;25(10):1257-1267. doi: 10.1007/s11864-024-01255-8. Epub 2024 Sep 16. Curr Treat Options Oncol. 2024. PMID: 39278999 Review.
218 results